<!DOCTYPE html>
<html>
<head>
<meta name="viewport" content="width=device-width, initial-scale=1">
<style>
a {
  text-decoration: none;
  display: inline-block;
  padding: 8px 16px;
}

a:hover {
  background-color: #ddd;
  color: black;
}

.previous {
  background-color: #f1f1f1;
  color: black;
}


</style>
</head>
<body>

<a href="index.html" class="previous">&laquo; Previous</a>
<!DOCTYPE html>
<html lang="en">
<head>
<title>CSS Template</title>
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1">
<style>
* {
  box-sizing: border-box;
}

body {
  font-family: Arial, Helvetica, sans-serif;
}

/* Style the header */
header {
  background-color: #1abc9c;
  padding: 30px;
  text-align: center;
  font-size: 35px;
  color: white;
}

/* Container for flexboxes */
section {
  display: -webkit-flex;
  display: flex;
  flex-direction:row;
}

/* Style the navigation menu */
nav {
  -webkit-flex: 1;
  -ms-flex: 1;
  flex: 1;
  background:linear-gradient(to bottom, #FFE53B 0%, #00FFFF 100%);
  padding: 20px;
}

/* Style the list inside the menu */
nav ul {
  list-style-type: none;
  padding: 0;
}

/* Style the content */
article {
  -webkit-flex: 3;
  -ms-flex: 3;
  flex: 3;
  padding: 10px;
}



/* Responsive layout - makes the menu and the content (inside the section) sit on top of each other instead of next to each other */
@media (max-width: 600px) {
  section {
    -webkit-flex-direction: column;
    flex-direction: column;
  }
}
/* Responsive for the div class of the image and the text */
html {
  box-sizing: border-box;
}
*, *:before, *:after {
  box-sizing: inherit;
}
body {
  margin: 0;
  background-color: #FFEEDD;
}
.textbox-1 {
  font-size: 1.25em;
  text-align: justify;
}
.row {
  display: flex;
  justify-content:space-around;
  padding:25px 0 ;
  max-width:1280px;
  margin:auto;
  
}
.flex {
  flex: 0 0 45%;
  background:#ccc;
}
.flex p{
  margin:0;
  padding:10px;
}
.object-fit{
  overflow:hidden;
  position:relative;
}
.object-fit img{
  position: absolute;
  top:50%;
  left:50%;
  height:auto;
  width:auto;
  min-width:50%;
  min-height:50%;
  transform:translate(-50%, -50%);
}
@supports (object-fit: cover) {
  .object-fit img  {
    position: absolute;
    left:0;
    top:0;
    height: 100%;
    width: 100%;
    transform: none;
    object-fit: cover;
  }
}
<!DOCTYPE html>
<html lang="en">
<head>
<title>CSS Template</title>
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1">
<style>
* {
  box-sizing: border-box;
}

body {
  font-family: Arial, Helvetica, sans-serif;
}

/* Style the header */
header {
  background-color: #1abc9c;
  padding: 30px;
  text-align: center;
  font-size: 35px;
  color: white;
}

/* Container for flexboxes */
section {
  display: -webkit-flex;
  display: flex;
  flex-direction:row;
}

/* Style the navigation menu */
nav {
  -webkit-flex: 1;
  -ms-flex: 1;
  flex: 1;
  background: linear-gradient(to bottom, #FFE53B 0%, #00FFFF 100%);
  padding: 20px;
}

/* Style the list inside the menu */
nav ul {
  list-style-type: none;
  padding: 0;
}

/* Style the content */
article {
  -webkit-flex: 3;
  -ms-flex: 3;
  flex: 3;
  padding: 10px;
}



/* Responsive layout - makes the menu and the content (inside the section) sit on top of each other instead of next to each other */
@media (max-width: 600px) {
  section {
    -webkit-flex-direction: column;
    flex-direction: column;
  }
}
/* Responsive for the div class of the image and the text */
html {
  box-sizing: border-box;
}
*, *:before, *:after {
  box-sizing: inherit;
}
body {
  margin: 0;
  background-color: #FFEEDD;
}
.textbox-1 {
  font-size: 1.25em;
  text-align: justify;
}
.row {
  display: flex;
  justify-content:space-around;
  padding:25px 0 ;
  max-width:1280px;
  margin:auto;
  
}
.flex {
  flex: 0 0 45%;
  background:#ccc;
}
.flex p{
  margin:0;
  padding:10px;
}
.object-fit{
  overflow:hidden;
  position:relative;
}
.object-fit img{
  position: absolute;
  top:50%;
  left:50%;
  height:auto;
  width:auto;
  min-width:70%;
  min-height:50%;
  transform:translate(-50%, -50%);
}
@supports (object-fit: cover) {
  .object-fit img  {
    position: absolute;
    left:0;
    top:0;
    height: 100%;
    width: 100%;
    transform: none;
    object-fit: cover;
  }
}
</style>
</head>
<body>
<header>
  <h2>Treatment</h2>
  
</header>

<section>
  <nav>
    <ul>
       <li><a href="treatment.html">Surgery</a></li>
      <li><a href="chemo.html">Chemotherapy</a></li>
      <li><a href="radio.html">Radiotherapy</a></li>
	  <li><a href="target.html">Targeted Therapy</a></li>
	  <li><a href="immuno.html">Immunotherapy</a></li>
    </ul>
  </nav>
  
  <article>
    <h1>Targeted Therapy</h1>
	<p>Targeted therapy is an innovative approach to cancer treatment that focuses on specific molecular targets associated with cancer cells, aiming to inhibit their growth and spread. In cervical cancer, targeted therapies have emerged as important options, particularly for advanced and recurrent cases. 
</p>
    <b><p>Types of Targeted Therapies</b>
<b><p>1.Antiangiogenic Agents</p></b>
<b><p><ul><li>Bevacizumab (Avastin):</p></b>
<ul><li><b>Mechanism:</b> A monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), preventing the formation of new blood vessels that tumors need to grow.</li>
<li><b>Indications:</b> Used in combination with chemotherapy for advanced cervical cancer or recurrent disease.</li>
<li><b>Efficacy: </b>Studies indicate that bevacizumab can improve progression-free survival (PFS) and overall survival (OS) when added to standard chemotherapy regimens.</li></ul>
<b><p>2.PARP Inhibitors</p></b>
Olaparib, Rucaparib, Niraparib:
<li><b>Mechanism: </b>These drugs target poly (ADP-ribose) polymerase (PARP), involved in DNA repair processes, particularly in tumors with homologous recombination deficiency.</li>
<li><b>Indications:</b> Emerging evidence suggests their use in patients with recurrent cervical cancer, especially those with specific genetic mutations.</li>
<b><p>3.Immune Checkpoint Inhibitors</p></b>
<b><li>Pembrolizumab (Keytruda):</li></b>
<li><b>Mechanism:</b> Blocks the PD-1 receptor on T cells, enhancing the immune response against cancer cells expressing PD-L1.</li>
<li><b>Indications:</b> Approved for use in recurrent or metastatic cervical cancer with PD-L1 expression.</li>
<li><b>Combination Therapy:</b> Often used alongside chemotherapy to enhance treatment efficacy.</li>
<b><p>4.HER2-Targeted Therapies</p></b>
<li><b>Trastuzumab (Herceptin):</b>
<li><b>Mechanism: </b>Targets the HER2 protein overexpressed in some cervical cancers.</li>
<li><b>Indications:</b> Investigated for use in HER2-positive cervical cancer patients, often in combination with other agents.</li>
<b><p>5.Tumor-Intrinsic Signaling Pathway Inhibitors</p></b>
<ul><li>Targeting various signaling pathways involved in tumor growth and survival, including mTOR inhibitors and EGFR inhibitors.</li></ul>
<a href="https://www.cancer.gov/types/cervical/treatment">Source</a>
  </article>
</section>

</body>
</html>





































